Posts

Rasonque mutation-level data point to a possible opening for competing pancreatic-cancer treatments

on
Newly disclosed FDA review data suggest Rasonque (daraxonrasib), Revolution Medicines’ pancreatic-cancer drug, may not work equally well across KRAS mutations. In the clinical-trial data, responses were strongest for tumors with KRAS G12V, more modest for the common G12D mutation, and weaker for G12R. Because G12D is the most common KRAS mutation in pancreatic cancer, the variation raises questions about how broadly the overall trial results apply to patients with that subtype. The report says Revolution shares fell by more than 6% after the disclosure. Analysts described the results as a possible opening for competitors developing mutation-specific G12D treatments or next-generation drugs. This is a potential competitive opportunity, not evidence that an alternative treatment has already proved superior. The broader Phase 3 trial still showed a significant overall benefit versus chemotherapy: median overall survival was 13.2 months with Rasonque versus 6.7 months with chemothe...

Early outlook on Merck’s tulisokibart in HS

on

GSK expands collaboration with Chai Discovery after lab tests

on

FDA expands Tecentriq use in a defined colon cancer group

on

General Medicine raises $120M to expand its healthcare store

on

Endeavor reports Phase 2b win for its investigational IPF drug

on

Viatris to buy Pacira for $1.65 billion, expanding non-opioid pain portfolio

on

TRex Bio and Retension price biotech IPOs totaling about $162 million

on

PhRMA sues to block CMS’s Medicare Part B foreign-price model

on

Virta Health reports its first profitable quarter

on

Petrelintide shows weight loss, but blood-sugar effect raises questions

on

argenx halts Phase 3 Vyvgart trial in Sjögren’s disease

on

ARPA-H launches SURPASS to speed and modernize clinical trials

on